How cancer hides from immune cells — and the molecular trick it uses
Cancer cells have a way of making themselves invisible to the immune system’s hunters.
When a T cell attacks a cancer cell, it does not do so at random. A precise molecular contact point is required: the immune synapse, a temporary but organized connection between the T cell and the cancer cell through which signals are exchanged that activate the T cell to kill. But tumors are evolutionarily resourceful — they have developed ways to disrupt that synapse before the killing can begin.
A study published in eLife describes how cancer cells use a specific protein transport system — clathrin-independent endocytosis mediated by a protein called EndoA3 — to remove two molecules from the cell surface that are critical for immune synapse formation: ICAM-1 and ALCAM. Endocytosis is the process by which a cell takes molecules from its outer membrane and moves them inside. In this case, those two proteins are not simply degraded; they are transported back to an internal depot — the trans-Golgi network — from where they can be strategically redistributed.
Recycling as a survival strategy
What makes this mechanism notable is the logistical sophistication. The cancer cell does not permanently delete ICAM-1 and ALCAM — it actively manages their presence on the surface. By temporarily withdrawing them when a T cell approaches, the tumor reduces the likelihood of effective recognition and attack. This is not passive invisibility but active immunological sabotage.
The finding is relevant to understanding immunotherapy — treatments that enlist the patient’s own immune system to fight cancer. Checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 have transformed oncology over the past decade, but a substantial proportion of patients do not respond. Part of that resistance may be explained by mechanisms like the one described here: the tumor disrupts the physical interaction with the T cell before inhibitory signaling even comes into play.
A new therapeutic target?
If EndoA3 is the key protein driving this transport system, it becomes a potential therapeutic target. Blocking EndoA3 could allow ICAM-1 and ALCAM to remain on the cancer cell surface longer, enabling better immune synapse formation and more effective T cell killing. Whether that works in practice without unwanted side effects is a question for preclinical and clinical studies — which have not yet been done.
The research reflects a broader pattern in cancer immunology: the more precisely we map the molecular communication between the immune system and tumors, the more potential intervention points we identify. But also: the more complex the puzzle turns out to be.